Defense World
05 Apr 2026, 06:17 UTC · 29w ago
Impact · against what's priced in
The article provides a comparative fundamental and sentiment analysis between CytomX and Adagene, favoring CytomX on institutional support and analyst targets. While the data is positive for both, it consists of lagging indicators and consensus targets rather than new clinical or financial catalysts.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish
CytomX Therapeutics has a consensus analyst target price of $13.44, implying a potential upside of 194.83%.
So whatA nearly 200% implied upside based on analyst consensus is a strong bullish signal for investors.
More positive than 93% of claims this week
CytomX Therapeutics maintains institutional ownership of 67.8%, compared to Adagene's 9.5%.
Continue reading
5 related stories
CytomX shows strong institutional backing at 67.8% and a significant consensus price target upside of 194.83%, supported by higher revenue and earnings than its peer Adagene.
Read from the article alone
No priced-in read yet
Adagene maintains a positive analyst outlook with a consensus target price of $7.67, representing a potential upside of 92.15%.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 78% of claims this week
Adagene has a consensus analyst target price of $7.67, indicating a potential upside of 92.15%.
More positive than 65% of claims this week
CytomX Therapeutics reports higher gross revenue and earnings than Adagene.
So whatBetter fundamental financials provide a safer baseline for valuation in the volatile biotech sector.
More positive than 52% of claims this week
CytomX Therapeutics exhibits a beta of 2.49, making it 149% more volatile than the S&P 500.
More negative than 64% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
Analysts view it as more favorable than Adagene due to a higher potential upside of 194.83%, higher revenue, and higher earnings.
More positive than 70% of ticker scores this week
The company received a 'Moderate Buy' rating from analysts.
More positive than 55% of ticker scores this week
The company beats CytomX on 7 of 13 factors and has a significant price target upside of 92.15%.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
More positive than 13% of relationship scores this week
[mutual] CytomX Therapeutics has a strategic collaboration with Bristol Myers Squibb.
More positive than 13% of relationship scores this week
[mutual] CytomX Therapeutics has a strategic collaboration with Amgen.
More positive than 13% of relationship scores this week
[mutual] CytomX Therapeutics has a strategic collaboration with Moderna.
More positive than 13% of relationship scores this week
[mutual] CytomX Therapeutics has a strategic collaboration with Regeneron.
−39.6%
Price is moving against the score
$2.41 vs $3.99 close before publication (Apr 2) · not market-adjusted
ADAG chart →−49.1%
Price is moving against the score
$2.32 vs $4.56 close before publication (Apr 2) · not market-adjusted
CTMX chart →
